Common AEs were neutropenia, leukopenia, increased ALT, increased AST, anemia, nausea, and diarrhea [77,78] The 53.5 months of median follow-up confirmed the improvement in OS (58.7 vs. 48.0 months) and PFS (44.2 vs. 31.0 months) for ribociclib plus ET, including patients less than 40 years of age (OS: 51.3 vs. 40.5 months) [79]. The gene discussed is GPT; the disease is neutropenia.